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IMPORTANCE High-cost biologic therapies have transformed themanagement of
immune-mediated inflammatory diseases. To optimize outcomes and reduce costs, dose
adjustment informed bymeasurement of circulating drug levels has been shown to be
effective in various settings. However, limited evidence exists for this approach with the
interleukin 12 and interleukin 23 inhibitor ustekinumab.
OBJECTIVE To evaluate clinical utility of therapeutic drugmonitoring for ustekinumab in
patients with psoriasis.
DESIGN, SETTING, AND PARTICIPANTS A prospective observational cohort of 491 adults with
psoriasis was recruited to themulticenter Biomarkers of Systemic Treatment Outcomes in
Psoriasis study within the British Association of Dermatologists Biologic and
Immunomodulators Register from June 2009 to December 2017; samples from some
patients were taken between 2009 and 2011 as part of a pilot study with the same inclusion
criteria.
EXPOSURE Serum ustekinumab level measured at any point during the dosing cycle using an
enzyme-linked immunosorbent assay.
MAIN OUTCOMES ANDMEASURES Disease activitymeasured using the Psoriasis Area and
Severity Index (PASI) score. Treatment response outcomes were PASI75 (75% reduction in
PASI score from baseline [primary outcome]), PASI90 (90% reduction of PASI score from
baseline), and absolute PASI score of 1.5 or less.
RESULTS A total of 491 patients (171 women and 320men; mean [SD] age, 45.7 [12.8] years)
had 1 or more serum samples (total, 853 samples obtained 0-56 weeks from start of
treatment) and 1 or more PASI scores within the first year of treatment. Antidrug antibodies
were detected in only 17 of 490 patients (3.5%). Early measured drug levels (1-12 weeks after
starting treatment) were associated with PASI75 response 6months after starting treatment
(odds ratio, 1.38; 95% CI, 1.11-1.71) when adjusted for baseline PASI score, age, and
ustekinumab dose. However, this finding was not consistent across the other PASI outcomes
(PASI90 and PASI score of1.5).
CONCLUSIONS AND RELEVANCE This real-world study provides evidence that measurement of
early serum ustekinumab levels could be useful to direct the treatment strategy for psoriasis.
Adequate drug exposure early in the treatment cycle may be particularly important in
determining clinical outcome.
JAMA Dermatol. 2019;155(11):1235-1243. doi:10.1001/jamadermatol.2019.1783
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P soriasis is a chronic immune-mediated skin disease af-fecting at least 2% of the population.1 Management ofpsoriasis has been transformed by therapeutic mono-
clonal antibody biologics, of which the first-line choices are
either adalimumab (a tumor necrosis factor inhibitor) or
ustekinumab (an interleukin 12 [IL-12] and IL-23 inhibitor).2
There iswide variation in response to these drugs,withmany
patients not responding (primary treatment failure) or losing
response over time (secondary treatment failure).3,4 Some of
this heterogeneitymaybe explainedbydifferences in thebio-
availability and quantity of drug available at the target tissue,
which in turn is influencedbyadherence,drugdose, andphar-
macokinetic covariates such as weight and drug immunoge-
nicity (development of antidrug antibodies [ADAs]).
Unlike most other biologics used for inflammatory dis-
ease, ustekinumab is dosed according to body weight; pa-
tients who weigh less than 100 kg are generally given 45 mg
ofustekinumabsubcutaneouslyevery12weeks,whereas those
weighing at least 100 kg are given 90mg subcutaneously ev-
ery 12 weeks.5 Despite this dosing schedule, evidence sug-
gests that ustekinumab dosing is suboptimal in some pa-
tients: clinical trialdatapreviouslyshowedthatdoseescalation
increased rates of achieving 75% reduction from baseline in
the Psoriasis Area and Severity Index (PASI) score (PASI75) in
partial responders (those achieving ≥50%but <75% improve-
ment frombaseline PASI score),6 while patientswith a higher
baseline bodymass indexhavebeen reported to receive in ex-
cessof the recommendedcumulativedoseduring the first year
of treatment.7 Similarly, response rates to ustekinumab inpa-
tients weighing 90 to 100 kg have been reported to be signifi-
cantly lower than in other weight groups, suggesting that the
standard 45-mg dose is inadequate in patients who are ap-
proaching the 100-kg threshold.8 On the other hand,
ustekinumab dosing is likely to be excessive in some pa-
tients; a recent phase 3b study reported that lengthening in-
tervals between ustekinumab doses did not affect mainte-
nanceof response.9Takentogether, these findings suggest that
individualizeddose optimization and therapeutic drugmoni-
toring (TDM) of ustekinumabmay have clinical utility.
Although several ustekinumab assays are commercially
available in both the United States and Europe,10-15 monitor-
ingof serumustekinumab levels isnotyetwidelyused in clini-
cal practice. This is partly owing to limited evidence for TDM
of this drug, in contrast to the strong correlationdescribedbe-
tween tumornecrosis factor inhibitor serum levels,ADAs, and
treatment responseacrossmultiple immune-mediated inflam-
matory diseases.16-20 Reports on the association between
ustekinumab level and response to treatment have been
inconclusive,21-25withbasic parameter requirements for TDM
(eg, therapeutic range and target drug level) yet to be estab-
lished in the context of psoriasis.
Because the first step toward defining such parameters is
to determine the association between drug levels and out-
come,we investigated thisusinga real-worldbioresource from
the largemulticenter cohort studyBSTOP (Biomarkers of Sys-
temic Treatment Outcomes in Psoriasis) within the UK phar-
macovigilance registryBADBIR (BritishAssociationofDerma-
tologists Biologic and Immunomodulators Register).
Specifically,weaimed toexplore theassociationbetweendrug
level and response on the same day the drug level was mea-
sured, and to explore the associationbetweenearly drug level
and response at 6 months, because maximum clinical utility
may lie in theability todetermineoutcomeandmodify therapy
prior to clinical relapse.
Methods
Patients and Setting
As described previously,20 BSTOP is a prospective multi-
center (n = 60)observational study,established in2011 to iden-
tify markers of outcomes to systemic therapies for psoriasis.
All UK adults fulfilling BSTOP inclusion criteria26 and en-
rolled in BADBIR27 were invited to participate. Venous blood
sampleswerecollectedbetweenJune2009andDecember2016
during routine clinic reviews; samples from some BSTOP pa-
tientswere takenbetween2009and2011aspartofapilot study
with the same inclusion criteria. Clinical response was as-
sessed longitudinally using thePASI score. The current analy-
sis includespatients receivingustekinumabmonotherapy,with
1 or more serum sample and 1 or more recorded PASI scores
within the firstyearof treatment (Figure 1).This studywascon-
ducted in accordancewith the2008DeclarationofHelsinki.28
Three studies provided samples and data: a pilot study Pre-
dicting Drug Response (approved by National Research Eth-
ics Service Committee London–South East 2; ethics approval
code EC04/031), BSTOP (approved by National Research Eth-
ics Service Committee London–South East 2; ethics approval
code 11/H0802/7), and its nested study Psoriasis Stratifica-
tion to Optimise Relevant Therapy Discovery (PSORTD) (ap-
proved by National Research Ethics Service Committee Lon-
don–LondonBridge;ethicsapproval code14/LO/1685).Written
informed consent was obtained from all participants before
enrollment.
Drug Level and ADAMeasurements
Venous blood was collected during clinic reviews and cen-
trifuged for 10 minutes (2000g) and serum aliquots were
Key Points
Question Can therapeutic drugmonitoring for the interleukin-12
and interleukin-23 inhibitor ustekinumab optimize treatment
pathways and outcomes in patients with psoriasis?
Findings This cohort study of 491 patients with psoriasis found
that early serum ustekinumab levels were associated with a
subsequent 75% reduction from baseline in Psoriasis Area and
Severity Index score, although this association did not hold across
other Psoriasis Area and Severity Index outcomes. Drug
immunogenicity appeared to be low, with antidrug antibodies
detected in only 17 of 490 patients (3.5%).
Meaning This study provides evidence that measurement of early
ustekinumab levels could be useful to direct treatment strategy in
patients with psoriasis; adequate drug exposure early in the
treatment cycle may be particularly important in determining
clinical outcome.
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frozen (–80°C). In this pragmatic study, samples were not
collected from every patient at every time point; most were
collected without reference to treatment administration.
Samples within the first year of treatment were sent to San-
quin for measurement of ustekinumab levels and ADAs. The
ustekinumab level assay was an enzyme-linked immunosor-
bent assay similar to a previously developed adalimumab
assay,29 but using IL-12 to capture ustekinumab, with rabbit
anti-ustekinumab for detection (lower limit of detection,
0.02 μg/mL). Antidrug antibodies were measured using a
previously described radioimmunoassay,30 with minor
modifications (ADA positive cutoff >12 arbitrary units/mL).
Specifically, 1 μL of serum diluted in freeze medium was
incubated with Sepharose-immobilized protein A in the
presence of 1-ng/test biotin-conjugated ustekinumab F(ab)2.
Nonbound serum components were removed by washing
before 50 μL of iodine 125–labeled streptavidin was added
in a 500-μL phosphate-buffered saline-albumin solution
(0.3% bovine serum albumin, 0.01M EDTA, 0.004% poly-
sorbate 20, and 0.05% sodium azide). After incubation and
washing, radioactivity was measured using a gamma coun-
ter. Assay results were converted to arbitrary units/mL cal-
culated from a 2-fold serially diluted calibration curve of a
polyclonal ustekinumab-specific rabbit anti-idiotype.31 This
assay format has limited drug tolerance32 but was previ-
ously shown to have better correlation with clinical
response vs drug-tolerant alternatives in patients with rheu-
matoid arthritis who were taking adalimumab.33
OutcomeMeasures
Primary treatment responsewasdefined as achievingPASI75,
withbaselinePASI scoredefinedas themost recent PASI score
recordedprior to thedate of the first drugdosewithin thepre-
ceding 6 months.3,34 Secondary outcomes were 90% reduc-
tion inPASI score frombaseline (PASI90) andPASI score of 1.5
or less (absolute PASI score of ≤1.5, which approximates to
PASI90; written communication, Nina Wilson, PhD, January
2019).
Statistical Analysis
Based on previous work using adalimumab drug levels,20
we explored the association between ustekinumab level and
response in 2 ways. First, we investigated the association
between drug levels and response on the same day of the
sample; second, we investigated whether drug levels
sampled early after treatment start are associated with
response at 6 months. Two data sets were therefore derived:
a data set comprising samples obtained at steady state (≥16
weeks after treatment start), with a corresponding PASI
score on the same day as the sample date, hereafter referred
to as the same-day response data set, and a data set com-
prising samples obtained early in the treatment course (1-12
weeks after treatment start), with a corresponding PASI
score at 6 months (122-243 days after treatment start), here-
after referred to as the 6-month response data set. Analyses
for PASI75 and PASI90 responses were restricted to patients
with a baseline PASI score higher than 10 as an accepted cri-
terion for severe disease,35 and to minimize confounding
due to prebiologic treatments. The latter is particularly rel-
evant in this real-world data set.
Descriptive Analysis
Adescriptive concentration effect curvewas generated to as-
sesswhether clinical responseplateaus beyonda certaindrug
level. Box plots were used to visually compare drug levels by
responder group in both the same-day response and6-month
response data sets.
Logistic Regression Analysis
Weusedunivariate logistic regressionmodelswiththe6-month
responsedata set toexplore theassociationbetweenearlydrug
levels and treatment response in the presence of other covar-
iates, including those previously identified as factors associ-
ated with response in the BADBIR cohort (eg, weight, race/
ethnicity, disease and treatmentduration, ustekinumabdose,
andbiologic-naïve status).36Given thatmost sampleswerenot
trough levels, we also included time of sample from last
ustekinumab dose as a covariate. For continuous covariates,
the best-fitting simple nonlinear transformation was chosen
based on reduction in the Akaike Information Criterion. Co-
variatesassociatedwith responseat significance levelofP < .10
were takenforwardtoamultivariable logistic regressionmodel.
Forward selection techniqueswere then used, with covariate
inclusion based on a significance level of P < .05. Multivari-
able models were derived for all 3 PASI outcomes (PASI75,
PASI90, and PASI score of ≤1.5). For PASI90 and PASI score of
1.5 or less, drug level was included as the first covariate and
retained at each stage, despite not being significant on uni-
variate analysis. Pseudo R2 and Akaike Information Criterion
were calculated to assess model fit. All analyses were under-
taken using Stata, version 14,37 on a complete case basis.
Figure 1. FlowDiagram of Patients Included in the Study
726 Patients receiving ustekinumab monotherapy
and providing serum samples
491 Patients with both a serum sample and recorded
PASI score ≤12 mo from treatment start
235 Excluded because missing
a serum sample and/or
recorded PASI score ≤12 mo
from treatment start
252 Patients with samples obtained
at steady state (≥16 wk after
treatment start)
248 Patients with samples obtained
early (≥16 wk after treatment
start)
148 Patients with baseline PASI
score >10 (same-day response
data set)
85 Patients with baseline PASI
score >10 (6-mo response
data set)
237 Patients with PASI score on
same date as sample obtained
144 Patients with PASI score at 6 mo
(122-243 d after treatment start)
PASI indicates Psoriasis Area and Severity Index.
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Results
Patient Cohort and Baseline Characteristics
Atotalof491patients receivingustekinumabmonotherapyhad
both serum samples and PASI scores availablewithin the first
year of treatment (Figure 1,Table 1). The cohortwas predomi-
nantlymale (320 [65.2%]),with amean (SD) bodymass index
(calculated as weight in kilograms divided by height in me-
ters squared) of 32.0 (7.3) and mean (SD) baseline PASI score
of 13.3 (6.8). A total of 201 patients (40.9%) were biologic-
naive, and 282 (57.4%) were receiving 45mg of ustekinumab
vs 209 (42.6%) receiving 90mg (Table 1). Patients not provid-
ing serum samples were excluded, but their baseline charac-
teristics were similar (eTable 1 in the Supplement).
Response to Treatment
A total of 348 patients (70.9%) achieved PASI75 at somepoint
within a year of starting treatment. PASI75 remains a stan-
dard measure of adequate treatment response in UK
guidelines.38
Drug Levels and ADAs
Drug levels were sampled according to standard clinical care.
Excludingsamplesobtainedonthedaythe firstdosewasgiven,
themedian timefromlastdosewas28days (interquartile range
[IQR], 16-57 days; range, 0-98 days; data available for 515
samples), median drug level was 1.19 μg/mL (IQR, 0.37-2.86
μg/mL; range 0-13.1 μg/mL; 800 samples), and ADAs were
detected in 17 of 490 patients (3.5%) in 20 samples obtained
29 to 350 days after starting treatment.
Relationship Between Drug Level and Response
All analyses consideredall eligible samples. Therewas amaxi-
mum of 4 samples per patient.
Descriptive Analysis
A concentration effect curve showed no clear evidence of an
associationbetweensteady statedrug levels andsame-dayab-
solute PASI (eFigure 1 in the Supplement). Median drug level
and spread of drug levels were similar between patients re-
corded to have responded and those who did not respond on
the samedayas the serumsamplewasobtained (same-day re-
sponse data set; eFigure 2 in the Supplement). However, pa-
tients achieving PASI75 at 6 months (6-month response data
set) on average hadhigher early ustekinumab levels (median,
2.78 μg/mL; IQR, 1.78-4.02 μg/mL; range, 0.02-9.78 μg/mL)
comparedwithpatientsnotachievingPASI75 (median, 1.83μg/
mL; IQR, 0.96-2.86 μg/mL; range, 0.02-9.00 μg/mL)
(Figure 2A), with overlapping ranges between the 2 groups.
A similar pattern was observed for the other 2 response out-
comes, PASI90 and PASI score of 1.5 or less (eFigure 3 in the
Supplement).
To explore the association between drug level, response,
and dose, we split box plot data by ustekinumab doses of 45
mgand90mg(Figure2B).Asexpected,patientswhoachieved
PASI75 had higher median drug levels than did nonre-
sponders within each dose group. This pattern was also evi-
Table 1. Summary Statistics for the Full Cohort, Same-Day Response Data Set, and 6-Month Response Data Set
Covariate
Full Cohort (491 Patients; 853 Samples)
Response Data Set
Same Day (148 Patients; 175 Samples)a At 6 mo (85 Patients; 119 Samples)a
Mean (SD)
Complete Data,
No. (%) Mean (SD)
Complete Data,
No. (%) Mean (SD)
Complete Data,
No. (%)
Baseline PASI score 13.3 (6.8) 452 (92.1) 16.6 (5.2) 148 (100) 16.3 (5.5) 85 (100)
Height, cm 172.2 (10.3) 463 (94.3) 172.4 (10.5) 140 (94.6) 172.1 (10.5) 81 (95.3)
Weight, kg 94.7 (22.7) 435 (88.6) 96.1 (23.7) 140 (94.6) 94.2 (22.9) 80 (94.1)
Waist, cm 105.8 (16.8) 420 (85.5) 106.5 (17.4) 131 (88.5) 105.2 (15.7) 77 (90.6)
BMI 32.0 (7.3) 427 (87.0) 32.3 (7.7) 136 (91.9) 31.7 (7.6) 78 (91.8)
Age, y 45.7 (12.8) 491 (100) 45.2 (13.1) 148 (100) 48.7 (13.3) 85 (100)
Disease duration, y 23.3 (13.1) 464 (94.5) 23.1 (13.1) 142 (95.9) 23.4 (13.0) 82 (96.5)
No. (%) No. (%) No. (%)
White race/ethnicity 421 (85.7) 491 (100) 123 (83.1) 148 (100) 70 (82.4) 85 (100)
Male sex 320 (65.2) 491 (100) 99 (66.9) 148 (100) 59 (69.4) 85 (100)
Inflammatory arthritis 101 (23.5) 430 (87.6) 26 (18.8) 138 (93.2) 24 (30.4) 79 (92.9)
Ever smoked 289 (61.2) 472 (96.1) 81 (55.9) 145 (98.0) 51 (61.4) 83 (97.6)
Palm psoriasis 93 (21.1) 441 (89.8) 30 (21.6) 139 (93.9) 19 (24.1) 79 (92.9)
Biologic naive 201 (40.9) 491 (100) 64 (43.2) 148 (100) 37 (43.5) 85 (100)
Dose 491 (100) 148 (100) 85 (100)
45 mg 282 (57.4) NA 82 (55.4) NA 48 (56.5) NA
90 mg 209 (42.6) NA 66 (44.6) NA 37 (43.5) NA
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); NA, not applicable; PASI, Psoriasis Area and
Severity Index.
a Summaries for the same-day response and 6-month response data sets are
restricted to patients with a baseline PASI score higher than 10.
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dent for the outcomes of PASI90 and PASI score of 1.5 or less
(eFigure4 in the Supplement).However, patientswhodidnot
achievePASI75while taking90mgofustekinumabhadslightly
higher median drug levels than did nonresponders taking 45
mg of ustekinumab, albeit with overlapping ranges and large
variability (Figure 2B).
Logistic Regression Analysis
Univariate logistic regression indicated that early drug level
was associatedwith 6-month PASI75 (6-month response data
set: odds ratio, 1.27; 95% CI, 1.04-1.56), but there was no evi-
dence of this association for the other 2 PASI outcomes
(eTable2 in theSupplement).Next,multivariablemodelswere
derived toexplore theassociationbetweenearlydrug level and
6-month response in the presence of other relevant covari-
ates. The finalmodel for PASI75 included drug dose, baseline
PASI score, and age aswell as drug level (odds ratio, 1.38; 95%
CI, 1.11-1.71) (Table 2), and shows increasing probability of re-
sponse with increasing drug level (Figure 3). The model also
suggests that patients taking the higher ustekinumab dose
(90mg) have a lower probability of response for a given drug
level (Figure 3). To explore this finding further, we inspected
box plots of drug levels split by weight and dose (eFigure 5 in
the Supplement). Despite overlapping ranges, these boxplots
Figure 2. Box Plots Comparing EarlyMeasured Drug Levels by Achievement of 75%Reduction
FromBaseline in Psoriasis Area and Severity Index at 6Months
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A, Split by response only. The nonresponse group contains 46 samples and the
response group contains 73 samples. B, Split by response and by ustekinumab
dose. The nonresponse group receiving 45mg of ustekinumab contains
18 samples, the response group receiving 45mg of ustekinumab contains
50 samples, the nonresponse group receiving 90mg of ustekinumab contains
28 samples, and the response group receiving 90mg of ustekinumab contains
23 samples. In both panels, the middle line is themedian, white circles are the
means, ends of boxes are the lower and upper quartiles, dark blue circles are
outliers (values1.5 times the interquartile range from the lower and upper
quartiles), and whiskers show theminimum andmaximum values (unless there
are outliers, in which case they are 1.5 times the interquartile range from the
lower and upper quartiles).
Table 2. Final MultivariableModels for Determining 6-Month Response
Covariate Coefficient (SE) OR (95% CI) P Value Pseudo-R2
Samples,
No.
Responders, No.
(% of Samples)
PASI75
Drug level 0.32 (0.11) 1.38 (1.11-1.71) .004
0.18 119 73 (61.3)
Baseline PASI
score
0.10 (0.04) 1.10 (1.01-1.20) .03
Age 0.04 (0.02) 1.04 (1.00-1.07) .03
90-mg Dose −1.43 (0.44) 0.24 (0.10-0.56) .001
PASI90
Drug level 0.14 (0.09) 1.15 (0.97-1.38) .11
0.10 115 45 (39.1)
Baseline PASI
score
0.10 (0.04) 1.11 (1.02-1.20) .01
Disease
duration
0.04 (0.02) 1.04 (1.01-1.08) .009
PASI score ≤1.5
Drug level 0.11 (0.08) 1.12 (0.96-1.30) .15
0.06 186 58 (31.2)Naive tobiologics
0.92 (0.33) 2.51 (1.31-4.81) .006
Ever smoked −0.70 (0.34) 0.50 (0.26-0.96) .04
Abbreviations: OR, odds ratio;
PASI75, 75% reduction from baseline
in Psoriasis Area and Severity Index
score; PASI90, 90% reduction from
baseline in Psoriasis Area and
Severity Index score.
Association of SerumUstekinumab Levels With Clinical Response in Psoriasis Original Investigation Research
jamadermatology.com (Reprinted) JAMADermatology November 2019 Volume 155, Number 11 1239
Downloaded From: https://jamanetwork.com/ on 03/25/2020
show slightly lower median drug levels in patients weighing
more than 100 kg and in patients taking the higher
ustekinumab dose.
Drug levelwasnonsignificant for the outcomesof PASI90
andPASI scoreof 1.5 or less, even taking into accountother co-
variates. Furthermore, significant covariateswerenot consis-
tent across the 3 models for different PASI outcomes within
the 6-month response data set. Finally, we performed a sen-
sitivity analysis by fitting the final model for PASI75 to very
early trough samples (21-28 days after treatment start). De-
spite smaller sample size and greater uncertainty around es-
timates, a similar associationwas seenbetweendrug level and
response (odds ratio, 3.71; 95%CI, 1.24-11.08) (eTable 3 in the
Supplement).
Discussion
Key Findings
To our knowledge, this is the largest study to date of
ustekinumab drug level monitoring in patients with psoria-
sis.We report evidence that earlyustekinumab levelswere sig-
nificantlyassociatedwith6-monthPASI75 response.This find-
ing has particular clinical and practical relevance because
assays tomeasure serumustekinumab levels are already com-
mercially available in both the United States and Europe.10-15
We also report a low rate (3.5%) of detectable ADAs to
ustekinumabwithin the first yearof treatment, comparedwith
the previously reported rate of 37.5% in a cohort of patients
takingadalimumabthatwasderivedfromthesameUKstudy.20
It is possible that this differential drug immunogenicity ac-
counts, at least partially, for significantly higher rates of drug
survival (length of time from initiation to discontinuation of
treatment) in patients taking ustekinumab compared with
those taking adalimumab.3
The finding that the higher ustekinumab dose is associ-
ated with a lower probability of response is perhaps surpris-
ing.Onepossible explanation is thatpatients taking thehigher
doseexhibit characteristics associatedwithpoor response that
have not been accounted for in our model. An alternative ex-
planation may be that a double dose of ustekinumab (90 mg
vs45mg) fails to adequately compensate for the increasedvol-
umeofdistribution in somepeoplewith ahigher bodyweight;
we noted that median drug levels were slightly lower in pa-
tients taking the higher ustekinumab dose and in patients
weighing more than 100 kg.
Our data set should allow for stable estimation of compa-
rable numbers (4-5) of covariates39 in each of the analyses for
earlydrug level vs the3differentPASIoutcomes.However,we
wereunable todemonstratea linkbetweenearlydrug level and
the other PASI outcomes, nor between steady state drug lev-
els and same-day response. It is therefore possible that the as-
sociationbetweenearlydrug levelandPASI75 isowing toaspu-
riousPvalueor statistical artifact. This contrastswith findings
foradalimumab,14where thesamestatistical approachshowed
that both early and steady state drug levels were associated
withallPASIoutcomes.Afundamentalexplanationfor thismay
lie indifferingmechanismsof biologic action: adalimumabdi-
rectly inhibits the inflammatory effector cytokine tumor ne-
crosis factor, whereas ustekinumab inhibits IL-12 and IL-23,
with the latter being amaster regulator of pathogenic Thelper
17 cell development.40 Just as the underlying biological ef-
fect is more complex for ustekinumab, it may be that the as-
sociation between drug level and response is correspond-
ingly convoluted.
Existing Literature
Toourknowledge, thereare fewother studies in this area, gen-
erally limited to descriptive or empirical analyses investigat-
ing the association between ustekinumab level and re-
sponse,which reportmixed results. Themost recent study in
psoriasis included prospective follow-up of only 27 patients,
but reportedsimilar findings toours in thatveryearlydrug lev-
els (week 6) were inversely correlated with subsequent re-
sponse (week 12).25 However, in line with our data, no asso-
ciation was detected between drug levels measured later (in
this case, at week 12) and same-day response.
The largest study in patients with psoriasis reported sig-
nificantly lower drug levels and PASI50 response rates in pa-
tientswithdetectableADAs comparedwith thosewithout de-
tectable ADAs.23 Finally, in a Dutch cohort of 41 patients with
psoriasis, therewasnocorrelationbetweenustekinumab level
and response; 3 of 41 patients (7.3%) developed ADAs.24
Larger-scale studies have been conducted in the context
of inflammatory bowel disease. It is possible that variability
in theamountofdrug lostvia the inflamedgutmeansthatsome
patients are less able to achieve adequate serum concentra-
tions, meaning that TDMmay have greater utility in this set-
ting.Ananalysis ofphase3 trial data (n = 1154) reportedaposi-
tive association of drug levels with clinical and endoscopic
improvement, and an inverse correlationwithC-reactive pro-
tein level.21 Only 2% of patients developed ADAs.
Strengths and Limitations
A strength of this study is high external validity, asmore than
50% of all UK patients with psoriasis taking biologics are reg-
istered in BADBIR, and 95% of UK dermatology centers pre-
Figure 3. Probability of Achieving 75%Reduction FromBaseline
in Psoriasis Area and Severity Index Score at 6Months Based on Early
Measured Drug Level, Split by UstekinumabDose
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scribingbiologics for psoriasis contributedata toBADBIR.Our
findingshighlight thepotential clinicalutilityof thiseasilymea-
surable early biomarker in optimizing subsequent response.
They also serve as a call to action for both industry and aca-
demia to develop cost-effective and widely available assays,
and to further validate the role of TDM in clinical practice.
One limitationofourstudy is that,of491patientswithboth
a serumsample andPASI scorewithin 1 year of treatment, the
same-day response data set included 148 patients and the
6-monthresponsedataset included85patients.Figure 1 shows
the dropoff in patient numbers at each stage of filtering.
Asecondlimitationrelates tothedifficulty inaccountingfor
thecomplexassociationbetweendrug levelandresponseusing
standard logistic regressionmodeling. This approachhas been
successfullyusedinothersettings,notablytodefineatherapeu-
tic rangeand targetdrug level for adalimumab.20However, it is
possible thatustekinumab’sextendeddosing intervalcompared
with adalimumabmay pose a particular hindrance in this con-
text, as a single or small number of drug levelsmay represent a
relatively poormeasure of total drug exposure. This issuemay
havebeenexacerbatedbypragmatic serumsampling andPASI
assessmentatroutineclinicalvisits,asopposedtohavingsamples
measuredandPASIassessmentsperformedonlyduring trough
periods.Topartiallyaddressthis issue,weaccountedforthetim-
ingof samplesby including time fromlastustekinumabdoseas
acovariate inmodeling,but thisdidnot remain in the finalmul-
tivariablemodelsafter theforwardselectionprocess.Finally, the
validity of our findings is limited towithin 1 year of the start of
treatment, as thiswas the selected cohort duration.
Conclusions
Despite the complexities outlined above, we did find a statis-
tically significant association between early drug levels (≤12
weeks) and6-month PASI75 response in patientswith psoria-
sis taking ustekinumab. This finding suggests that adequate
drug exposure early in the treatment cycle may be particu-
larly important in determining clinical outcome with
ustekinumab. However, our statistical approach did not take
into account patient-level pharmacokinetic parameters such
as volume of distribution and clearance, nor potential differ-
ences in evolution of PASI score over time vs changing drug
levels. Therefore, future work should focus on pharmacoki-
netic-pharmacodynamic modeling of the whole time course
of response to ustekinumab.41 This modeling may be of par-
ticular relevance forbiologicswithmoreupstreamtargets, such
asdifferentiationpathwaycytokinesasopposed toeffector cy-
tokines. Further investigation to confirm the clinical utility of
TDMof ustekinumab and other biologics is a key step toward
personalization of treatment regimens across multiple im-
mune-mediated inflammatory diseases.
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